Kornimate/medical-research-clean huggingface dataset:
the predictive role of hpv integration in hsil and cervical cancer

Conditions: HPV Integration

Summary: the stratified analysis by the level of hpv dna integration in hsil and cervical cancer will be drawn to explore whether the status of hpv integration makes any difference in the progression of cervical cancer. the purpose of the research is to reduce the miss of cervix lesions and prove that hpv integration detection is sensitive in cervical cancer precise screening.


Eligibility criteria:
inclusion criteria: * hpv-positive patients； patients have completed hpv detection, tct, and hpv integration detection before surgery or biopsy； patients with priced diagnoses accepted treatment according to asccp risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors； patients who are voluntary participants in this research and cooperate to follow-up with subscribing informed consent. exclusion criteria: * patients who are not suitable for the trial； patients existing other subtype malignancy tumors are still in treatment.
neo-tace-haic for bclc b stage hcc

Conditions: Hepatocellular Carcinoma

Summary: hepatocellular carcinoma (hcc) patients is a common disease in the east asia. although bclc (barcelona clinical liver cancer) system recommend to transarterial chemoembolization (tace) for bclc b stage patients, increasing studies suggested that hepatic resection provided survival benefit for those patients. however, a relative high recurrence risk leads surgeons to investigate the value of preoperative treatment. recently, folfox (oxaliplatin and 5-fluorouracil) based hepatic artery infusion chemotherapy (haic) exhibited high response rate for unresectable hcc. pilot study showed tace combined haic (tace-haic) had better tumor response, with low progression disease rate. whether tace-haic would improve survival for patients with bclc b stage is need to further to study. a randomized clinical trial compared neo-tace-haic with surgery versus surgery alone is aimed to answer this question.


Eligibility criteria:
inclusion criteria: * • age 18-75 years; * bclc b stage and tumor number \<=4; * patients with resectable primary hepatocellular carcinoma; * child-pugh a or b (7 score) liver function; * the volume of residual liver more than 30% exclusion criteria: * • with unresectable hcc * pregnant woman or sucking period; * with other malignant cancer; * received anti-hcc therapy before this study
measurement of gait using opal apdm and gait mat in parkinsonism

Conditions: Parkinsonism

Summary: the project is a prospective trial comparing zeno/gaitrite and apdm® in a cohort of persons living with parkinsonian disorders. ambulatory patients with a parkinsonian syndrome and who are able to provide informed consent will participate in the assessments. outcome variables include selected gait and balance parameters such as cadence, gait-cycle, stride-length, stride-velocity, turning duration, turning steps, postural sway and anticipatory postural control. these parameters will be measured by the portable inertial sensors developed by apdm® and the zeno/gaitrite.

testing participants after screening and consenting will: 1. have their height measured and fit with the apdm opals (each device is a two inch square attached by velcro), one device is attached to each leg, each arm, and the trunk and chest and receive an introduction to walking on the gait mat. 2. participants are then asked to walk at a self selected walking speed down the gait mat. the participants will complete multiple passes (8-10 passes, total 75-100 feet) across the gait mat while wearing the apdm units to concurrently collect all temporal and spatial data needed to answer the research question. the zeno mat is the intended primary gait mat for this study. the gaitrite will only be utilized in the case of a technical issue with the zeno in order to insure completion of the data collection.

Eligibility criteria:
inclusion criteria 1. adults between the ages of 18 and 80 years of age with a primary diagnosis of pd and similar parkinsonian syndromes 2. individuals able to walk 100 feet independently, with or without the use of an assistive device (walker, cane) and follow simple instructions. 3. individuals with sufficient physiological systemic support to participate in the study protocol exclusion criteria 1. inability to speak english secondary to the need to understand and follow multistep directions 2. a secondary diagnosis (musculoskeletal, cardiopulmonary, neurological) that excludes participation in the study 3. inability to ambulate 100 feet independently with or without an assistive device. 4. inability to follow simple instructions necessary for completion of the testing tasks.

Keywords: parkinson's disease gait
effect of extracorporeal shock therapy for dysmenorrhea

Conditions: Primary Dysmenorrhea

Summary: this study was carried out upon forty women diagnosed as primary dysmenorrhea. they were selected from outpatient clinics of gynecology of ain shams university hospital, cairo university. their age ranged from 25-35 years, bmi\<30kg/ m².

patients with primary dysmenorrhea diagnosed by a physician, spondylolisthesis and chronic low back pain were excluded from the study. they were randomly assigned into two equal groups (a\& b). group (a) consisted of twenty subjects, with an average age 29.2±1.9yrs, and bmi 27.28±2.1kg/m2 who received extracorporeal shock waves. group (b) consisted of twenty patients, with an average age 28.58±2.2yrs, and bmi 28.92±0.7kg/m2 who received sham technique. a hot pack was used for 15 minutes for both groups (a\&b) before the treatment.

Eligibility criteria:
criteria: inclusion criteria: * forty virgin females. * their age ranged between 25 to 35 years old. * body mass index (bmi) \<30kg/ m². exclusion criteria: * females with pelvic pathology as endometriosis. * females have irregular menstrual cycles. * females have secondary dysmenorrhea.
calmodulin gene mutations in patients with ventricular arrhythmia of unknown origin - a screening study

Conditions: Ventricular Tachycardia

Summary: the aim of this study is to screen a well characterized patient population with ventricular tachycardia of unknown origin and treated with an implantable cardioverter-defibrillator (icd) for mutations in the calmodulin genes.

patients with ventricular tachycardia of unknown origin and treated with an implantable cardioverter-defibrillator (icd) will be asked to participate in the study. for patients with results showing mutations in the calmodulin genes, family members (parents, siblings and children) will also be asked to participate in the study. for under age patients and relatives who agree to participate, informed consent will also be taken from their custodian.

Eligibility criteria:
inclusion criteria: * patients with ventricular tachycardia of unknown origin that have been treated with an icd * signed and dated informed consent exclusion criteria: - inability to provide informed consent
clinical and echocardiographic management of patients with heart failure and diabetes: scodiac follow up study

Conditions: Diabetes; Heart Failure

Summary: the study has been carried out to determine diagnostic and therapeutic pathways in a group of hf diabetic patients and to verify whether the use of innovative antidiabetic therapies could modify echocardiographic parameters and influence cardiological therapy.

406 patients affected with heart failure and type 2 diabetes mellitus, referred to cardiologists and diabetologists of pertaining healthcare districts in campania, and followed for at least one year between 2018 and 2019, were enrolled in this retrospective study and divided in group a, composed of 136 hf diabetic patients with preserved ejection fraction (hf-pef) (\>45%) and group b, formed of 270 hf diabetic patients with reduced ef (hf-ref) (≤45%). all patients had performed periodic clinical evaluations and an echocardiographic exam every 12 months. anthropometric parameters, hf etiology, co-morbidities, complications and ongoing therapies were collected.

Eligibility criteria:
inclusion criteria: * age at least 65 years * presence of chronic hf, defined as a stable clinical syndrome with typical symptoms and signs and echocardiographic evidence of cardiac involvement * new york heart association (nyha) class ii-iii * diagnosis of t2dm from at least 2 years exclusion criteria: * cardiac surgery performed during the last year * age less than 65 years * significant valvulopathies * malignant neoplasms * advanced chronic kidney disease

Keywords: diabetes heart failure ejection fraction
a reinforcement approach to improve diabetes management

Conditions: Type 1 Diabetes

Summary: the purpose of this project is to evaluate the efficacy of a behavioral economic intervention to improve self monitoring of blood glucose (smbg) in adolescents and young adults with t1d. the intervention will reinforce patients for conducting smbg, with escalating reinforcers provided when patients achieved sustained periods of testing at least 4 times/day at appropriate intervals. a 6-month trial will be conducted in which 60 patients will be randomized to: (1) standard care or (2) standard care plus the reinforcement intervention.


Eligibility criteria:
inclusion criteria: 1. age 12-21 years old; 2. diagnosis of type 1 diabetes (t1d) \>12 months via ada guidelines 3. receiving diabetes treatment at yale pediatric diabetes clinic and not meeting clinical care guidelines 4. smbg user with clinical recommendations to test \>4 times/day and using a device that allows for remote uploading (e.g., aviva, contour, freestyle, lifescan, etc.; equipment for uploading will be provided); 5. access to a computer with internet for uploading and sending smbg data; 6. access to a cell phone with text messaging capabilities and willing to text after smbg testing and receive messages about reinforcement; 7. english speaking, able to read at \>5th grade level, and pass an informed consent quiz; and adequate knowledge of insulin dosing and dietary recommendations for managing t1d. exclusion criteria: 1. have a major psychiatric or neurocognitive disorder (e.g., severe learning impairment) that would inhibit participation; 2. have a major visual impairment; 3. have a significant other medical condition that impacts diabetes management (e.g., asthma, rheumatoid arthritis, or other condition that requires steroid treatment); 4. plan to switch insulin delivery mode (injection to pump or vice versa) in the next 12 months, or have recently switched; 5. are participating in another clinical trial.
integrative gastroenterology - an observational trial

Conditions: Crohns Disease; Ulcerative Colitis; Irritable Bowel Syndrome

Summary: this study aims to test, if a two-week integrative therapy in an internal medicine ward will improve symptoms, disability and quality of life in patients with inflammatory bowel disease or irritable bowel syndrome.a it shall further be tested, if those changes are associated with attitudes and experiences towards complementary and alternative medicine, anxiety, depression and stress perception as well as body awareness and responsiveness.

see above

Eligibility criteria:
inclusion criteria: * 18 years or older * diagnosed with irritable bowel syndrome (ibs) or inflammatory bowel disease (ibd) * written informed consent exclusion criteria: * participation in other clinical studies
the efficacy of n-acetylcysteine on alleviating symptom caused by lugol chromoendoscopy

Conditions: Esophageal Squamous Cell Carcinoma

Summary: lugol chromoendoscopy is essential in detecting and characterizing squamous cell carcinoma of esophagus. esophageal irritating symptom has been reported as an common adverse event, which could be alleviated by sodium thiosulfate solutions. however, sodium thiosulfate was not widely available. n-acetylcysteine has been previously used as a mucolytic reagent, we propose that it may also be used to alleviate irritating symptoms caused by lugo's chromoendoscopy. a prospective, non-inferior, randomized double-blind clinical trial was designed to study the efficacy of n-acetylcysteine solutions in relieving esophageal discomfort .


Eligibility criteria:
inclusion criteria: * patients at risk of esophageal squamous cell cancer including those over 50 years old, or over 45 years old with family history of esophageal squamous cell cancer; * patients with suspected esophageal lesions by screening endoscopy; * patients requiring surveillance after endoscopic resection or radiotherapy for esophageal squamous cell cancer one year later。 exclusion criteria: * patients allergic to iodine or with hyperthyroidism; * patients with advanced esophageal cancer, esophageal varices, esophageal ulcer or other conditions inadvisable for lugol chromoendoscopy; * patients with severe gastroesophageal reflux disease or reflux symptoms which may interfered with the outcome measures of current study; * patients with postoperative esophageal stenosis affecting endoscopic observation; * patients with serious comorbidities that cannot tolerate un-sedated gastroscopy; * patients who could not cooperate with the observation including patients with mental disorders, severe neurosis or dysgnosia; * patients undergoing sedation or general anesthesia during endoscopy. * patients who do not agree to sign informed consent forms or follow the trial requirement.

Keywords: lugol chromoendoscopy adverse event
creatine supplementation and diabetes

Conditions: Diabetes; Renal Function

Summary: creatine supplementation is capable of improving glucose tolerance in healthy subjects. the researchers aim to investigate whether this supplement can affect metabolic control in diabetic patients.


Eligibility criteria:
inclusion criteria: * males and females type 2 diabetic patients * glycated hemoglobin between \> 9% * non insulin users * physically inactive * only metformin and/or sulfonylurea users * bmi \> 30 kg/m2 * age of years \> 50 y

Keywords: creatine supplementation exercise training
genetic biomarkers in tissue samples from patients with osteosarcoma

Conditions: Osteosarcoma

Summary: this clinical trial studies genetic biomarkers in tissue samples from patients with osteosarcoma. studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in dna and identify biomarkers related to cancer

study subtype: ancillary/correlative observational study model: cohort time perspective: retrospective biospecimen retention: samples with dna biospecimen description: tissue study population description: samples from the cog sampling method: non-probability sample primary objectives: i. to use pet sequencing to analyze dna from ten human primary osteosarcoma samples, along with matched normal tissue where available. outline: tissue samples are analyzed for translocations and deletions and analyzed using polymerase chain reaction (pcr) or fluorescence in situ hybridization (fish).

Eligibility criteria:
inclusion criteria: * samples from the cog tissue repository
fractionated stereotactic radiotherapy vs. single session radiosurgery in patients with larger brain metastases

Conditions: Cerebral Metastases of Solid Cancers

Summary: phase iii trial comparing local control and side effects after fractionated stereotactic radiotherapy and single session radiosurgery in patients with larger brain metastases (2-4 cm)

this is a prospective, multicenter randomized trial comparing local control and side effects after fractionated stereotactic radiotherapy with 12 x 4 gy and single session radiosurgery according to rtog 9005 in patients with larger brain metastases (2-4 cm). patients will be randomized to either fractionated stereotactic radiotherapy with 12 x 4 gy or radiosurgery with 1 x 18 gy (2-3 cm) or 1 x 15 gy (3-4 cm) as defined by the rtog 9005. randomization will be stratified by metastasis volume and histology.

Eligibility criteria:
inclusion criteria: * age \> 18 years, no upper age limit * karnofsky performance score \> 50 points * expected survival \> 3 months * 1-10 cerebral metastases of metastatic solid cancer * indication for local radiotherapy * patients must be able to understand the protocol and provide informed consent exclusion criteria: * whole brain radiotherapy no longer than 6 weeks before the start of stereotactic radiotherapy or planned whole brain radiotherapy after stereotactic radiotherapy * prior irradiation of the cerebral metastasis that is to be treated in the study * relevant overlap of prior radiation fields with the metastasis that is to be treated in the study * metastasis in the brainstem * contraindication for cerebral mri * metastasis that is to be treated in the study can't be visualized in contrast-enhanced t1 mri sequence * pregnant or lactating women * abuse of illicit drugs, alcohol or medication * patient not able or willing to behave according to protocol * participation in another clinical trial
rivaroxaban versus low-molecular-weight heparin for preventing thrombosis in cancer patients

Conditions: Neoplasms

Summary: the study is designed to compare the efficacy and safety of oral rivaroxaban and subcutaneous low-molecular-weight heparin in preventing femoral venepuncture associated thrombosis among cancer patients.


Eligibility criteria:
inclusion criteria: * age 18 to 85 * histologically or cytologically confirmed advanced or metastatic solid tumors * patients will be received femoral venepuncture for apheresis by cell separator, which is the necessary process to perform following adoptive cell immunotherapy. * estimated life expectancy \> 3 months * adequate hematologic function, with wbc ≥ 3000/microliter, hemoglobin ≥ 9 g/dl (it is acceptable to have had prior transfusion), platelets ≥ 75,000/microliter; pt-inr \<1.5 (unless patient is receiving warfarin in which case pt-inr must be \<3), ptt \<1.5x uln * adequate renal and hepatic function, with serum creatinine \< 1.5 mg/dl, bilirubin \< 1.5 mg/dl (except for gilbert's syndrome which will allow bilirubin ≤ 2.0 mg/dl), alt and ast ≤ 2.5 x upper limit of normal. exclusion criteria: * known conditions associated with high risk of bleeding, known history of hemorrhagic diathesis * platelet count \< 50 000 g/l * active bleeding * patients with a history of autoimmune disease, such as but not restricted to, inflammatory bowel disease, systemic lupus erythematosus, ankylosing spondylitis, scleroderma, or multiple sclerosis. autoimmune related thyroid disease and vitiligo are permitted. * patients with obstructive jaundice * patients with spleen hyperfunction * presence of an active acute or chronic infection including: a urinary tract infection, hiv (as determined by elisa and confirmed by western blot). patients with hiv are excluded based on immuno-suppression, which may render them unable to respond to the vaccine; patients with chronic hepatitis are excluded because of concern that hepatitis could be exacerbated by the injections. * pregnant or breast-feeding women，or lack of effective contraceptive treatment for women of childbearing age.;
mobile video education to improve patient clinician communication during prenatal clinic visits

Conditions: Patient Empowerment

Summary: the goal of this clinical trial is to test an animated video delivered by text message in patients whose pregnancies are complicated with fetal anomalies. the main question it aims to answer is: does the video intervention prepare parents to talk to the doctors during prenatal appointments? participants will be randomized to receive either the video intervention or links to the clinic's webpages. they will complete an enrollment survey before their appointment and a follow up survey after their appointment. the researchers will compare the video and webpage groups to see which group reports engaging in more of the identified best-practices of communication.


Eligibility criteria:
inclusion criteria: * pregnant patient scheduled for an appointment at the children's wisconsin fetal concerns center for a fetal anomaly. * able to speak and understand english (intervention videos are only currently available in english). * age of 18 years or older. exclusion criteria: * pregnant patient's appointment at children's wisconsin fetal concerns center is not for a fetal anomaly (e.g., screening only, past pregnancy with anomaly only cause of appointment) * pregnant patient is considering termination of pregnancy.

Keywords: prenatal care congenital abnormalities communication mobile health
effects of telephone consultations on discharged liver cancer

Conditions: Hepatocellular Carcinoma

Summary: the aims of this three-year study are to: 1. from patients and family perspective to explore the needs for home care after receiving tace, pei, and rfa 2. develop a telephone follow-up and consultation program and examine its effect on self-efficacy, anxiety, depression and quality of life in liver cancer patients receiving non-surgical treatment.

in the first year, a longitudinal mixed method with quantitative and qualitative method will be used. the distress management tool, the hospital anxiety and depression scale, and the short form-12 quality of life will be used to assess patients' care needs, anxiety, depression, and quality of life in the quantitative method. data will be analyzed by descriptive, pearson's correlation, and stepwise regression for each time point. tape-recorded and in-depth interviews with semi-structured interview guidelines will be used in qualitative method to interview the cancer patients who are scheduled to be discharged after treatment. content analysis will be used to analyze the interview content. in the second and third year, randomized control trial will be used to recruit eligible subjects from inpatients in oncology wards in one medical center in taipei. the eligible subjects will be randomized into a control or experimental group. the patients in the control group will receive usual care and those in the experimental group will receive seven instances of telephone follow-up or face-to-face education (the day before discharge and during the first, second, third, fourth, sixth, and eighth weeks after discharge).data will be analyzed by independent t-test, one-way analysis of variance, and generalized estimating equations.

Eligibility criteria:
inclusion criteria: * patients with liver cancer in non-surgical treatment * aged above 18 * those who are wiling to participate in the research exclusion criteria: * none

Keywords: hepatocellular carcinoma needs telephone consultation
reading performance with a video magnifier

Conditions: Macular Degeneration

Summary: the most common goal for patients with vision loss who present for vision rehabilitation is to be able to read. the video magnifier (a device which combines a video camera and a screen to view the print being magnified) is the device which most often allows low-vision individuals to read successfully for extended periods of time. previous studies on the outcomes of vision rehabilitation have not identified which components of the vision rehabilitation are effective. the hypothesis of this project is that providing a video camera magnifier, with basic training in operating the device, will allow patients to enhance both objective reading ability and subjective report of reading competence.

patients will be given a video magnifier at initial consultation or at the end of vision rehabilitation

Eligibility criteria:
inclusion criteria: * central field loss and decreased visual acuity in the better seeing eye (\ 20/400). * new patient at meei low vision rehabilitation clinic exclusion criteria: * dementia (mini-mental state examination) * clinical depression (geriatric depression scale) * patients who previously received vision rehabilitation * patients who have previously owned a desktop video magnifier

Keywords: amd vision rehabilitation video camera magnifier ivi dass